Elicio Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Elicio Therapeutics, Inc. (NASDAQ: ELTX) is a clinical-stage biotechnology company focused on developing next-generation immunotherapies to treat aggressive cancers. The company leverages its proprietary Amphiphile (AMP) platform, which is designed to deliver investigational immunotherapies directly to the lymph nodes—the command center of the immune system—to stimulate robust and durable immune responses. Elicio's lead product candidate is ELI-002 7P, an off-the-shelf therapeutic vaccine targeting seven Kirsten rat sarcoma viral oncogene homolog (KRAS) driver mutations, which are prevalent in approximately 25% of all solid tumors, including over 90% of pancreatic cancers. The company is also advancing preclinical programs, including ELI-007 (targeting BRAF-driven cancers) and ELI-008 (targeting TP53-mutated cancers).
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Following the Phase 2 AMPLIFY-7P primary endpoint miss in the ITT population, Elicio refined its Phase 3 development strategy to focus exclusively on R0 completely resected PDAC patients (who showed a strong post-hoc DFS benefit with a hazard ratio of 0.65) and to extend treatment duration with additional dosing.
Expected impact: Aims to achieve regulatory approval (BLA) for ELI-002 7P as an off-the-shelf monotherapy in the adjuvant PDAC setting.
Advancing preclinical candidates ELI-007 (targeting BRAF-driven cancers) and ELI-008 (targeting p53 hotspot mutations) toward Investigational New Drug (IND) filings and subsequent Phase 1 clinical trials.
Expected impact: Broadens the company's oncology pipeline beyond mKRAS mutations to target other high-prevalence cancer drivers.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Supports the clinical expansion of ELI-002 7P into the neoadjuvant setting for borderline and resectable PDAC, evaluating the vaccine in combination with chemotherapy and an anti-PD1 checkpoint inhibitor.
Terms: Funded by The Lustgarten Foundation; conducted by Memorial Sloan Kettering Cancer Center.